

TEACHING FILES (GRAND ROUNDS)

PERSISTENT PSEUDOMONAS AERUGINOSA INFECTION IN A CHILD WITH CYSTIC FIBROSIS – HOW TO MANAGE?

Lavina Desai¹, Ira Shah²

¹Seth G S Medical College, Mumbai, India, and ²Pediatric Infectious Diseases, Levioza Health Care, Mumbai, India.

KEYWORDS

CF, pseudomonas

ARTICLE HISTORY

Received 7 July 2018

Accepted 1 September 2018

Clinical Problem

A 6 month old girl was diagnosed to have cystic fibrosis (CF) in 2009 in view of recurrent respiratory tract infections and diarrhea with malnutrition. Sweat chloride conductivity test was positive (75 mmol/L equivalent NaCl). She tested positive for both the alleles of F508 mutation. She was started on pancreatin supplements and vitamins A, D, E and K following which her diarrhea subsided. She was hospitalized for the first time in December 2011. Her sputum cultures subsequently grew *Burkholderia cepacia*, *Streptococcus pneumoniae*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* over the next few months. She was put on tobramycin nebulization along with N-acetyl cysteine nebulization. Her sputum cultures continued to grow *Pseudomonas aeruginosa* on and off. In December 2013, the *P. aeruginosa* was resistant to tobramycin and she was treated with oral ciprofloxacin and nebulized Colistin for 6 weeks. She was alright till February 2014 when she was hospitalized with pneumonia and was treated with Amikacin and Ceftazidime for 4 weeks. In view of poor weight gain, a percutaneous endoscopic gastrostomy (PEG) tube insertion was done in April 2014. She continued to have recurrent pneumonias due to *P. aeruginosa* for which she was on nebulized Colistin and finally succumbed to her disease in February 2018.

How to manage persistent pseudomonas aeruginosa infection in cystic fibrosis?

Discussion

Cystic Fibrosis (CF) is an autosomal recessive disorder found commonly in Caucasians reported even from India. (1,2) The gene for CF is located on the long arm of chromosome 7 and there are more than 300 identified mutations in CF. Delta F508 mutation was identified in 44% of CF alleles in a review of genotypes of south Asian patients, considerably lower than the reported frequency of 66% in the worldwide CF population. (3,4) This disease is characterised by abnormally thick secretions in respiratory, gastrointestinal and reproductive tract and sweat glands. The common presentations are meconium ileum in

neonates, recurrent lower respiratory tract infections (*Pseudomonas* spp pneumonia, bronchiectasis), steatorrhea, azoospermia, and in late stages hepatobiliary and endocrine pancreatic dysfunctions. (2) Respiratory involvement typically causes persistent productive cough, breathlessness, hyperinflation of lung fields on chest X-ray and pulmonary function tests that are consistent with obstructive disease. Transient infections with pathogenic organisms occur early in life. *Staphylococcus aureus* and *Haemophilus Influenzae* colonization is common during early childhood but ultimately *Pseudomonas aeruginosa* is isolated from CF patients due to impaired clearance directly induced by a defective CFTR gene. (5) *Pseudomonas aeruginosa* colonization is highly prevalent in the lungs of cystic fibrosis patients and leads to progressive pulmonary function decline and its eradication is particularly challenging. (6,7)

Treatment of CF is focused on maintaining lung function near normal by controlling respiratory infection and clearing airways of mucus, administering nutritional therapy and managing complications. Chest physiotherapy along with bronchodilators, antibiotics, mucolytics, anti-inflammatory treatments, and pancreatic enzyme supplements are commonly used. (8,9) Nebulized tobramycin and Colistin are widely used in treatment of Pseudomonas infection which help slow down growth, maintain lung function, and reduce frequency of pulmonary exacerbations. (10,11) When first detected, Pseudomonas infection is treated with only inhaled tobramycin for 28 days. Inhaled Colistin with oral ciprofloxacin is similar in effect. (6) Aerosolized drugs concentrate in the conducting zone of the lung and systemic administrations concentrate in the respiratory zone, since both are colonized, a combination of systemic and nebulized antibiotics is the most helpful. (10) Liposomal amikacin for inhalation is under development that enhances drug delivery and retention in CF airways via drug incorporation into liposomes, it prolongs off-drug periods and helps manage chronic Pseudomonas lung infections. (11)

To cope with malnutrition and improve age-dependent anthropometrics, the CF Foundation recommends enteral tube feeding for adequate nutrition and growth in individuals unable to consume adequate calories and protein. (7,12) As recent as February 2018, a new drug was approved by the FDA called ivacaftor/tezacaftor. It is a CFTR modulator and was approved for use in

CONTACT Lavina Desai

Email : lavinadesai16@gmail.com

Address for Correspondence: Lavina Desai,
Seth G S Medical College, India.

©2018 Pediatric Oncall

patients above 12 years of age who have two copies of F508 mutation (F508del). In late-stage clinical trials, people with two copies of F508del mutation showed an improvement in lung function by 4% compared to those taking a placebo. Another novel treatment that is under investigation is ataluren which is currently licensed for use in Duchenne muscular dystrophy patients and is being considered for use in CF patients and a nonsense CFTR gene mutation. In addition a new protease inhibitor has been discovered that prevents activation of epithelial sodium channels in the airways of people with cystic fibrosis and hence has the ability to help in airway hydration and mucus clearance. (13) We could not try any of these agents in our patient as they were unavailable.

Compliance with Ethical Standards

Funding: None

Conflict of Interest: None

References:

1. Kabra SK, Kabra M, Lodha R, Shastri S. Cystic fibrosis in India. *Pediatr Pulmonol.* 2007;42:1087-94.
2. Sabra SK, Kabra M, Verma GC. Cystic Fibrosis-an Indian perspective on recent advances in diagnosis and management. *Indian J Pediatr.*1996;63:189-198.
3. Prasad R. Molecular Basis of Cystic Fibrosis disease: An Indian Perspective. *Indian J Clin Biochem.* 2010;25:335-341.
4. Ashavaid TF, Raghavan R, Dhairyawan P, Bhawalkar S. Cystic Fibrosis in India. *J Assoc Phys India.* 2012;60:39-41.
5. Julie PK. Cystic Fibrosis: Clinical manifestations and diagnosis. Available on <https://www.uptodate.com/contents/cystic-fibrosis-clinical-manifestations-and-diagnosis>. Accessed on 1st June 2018
6. Simon RH. Cystic Fibrosis: Antibiotic Therapy for chronic pulmonary infection. Available on <https://www.uptodate.com/contents/cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection>. Accessed on 1st June 2018
7. Schwarzenberga SJ, Hempstead SE, McDonald CM, Powers SW, Wooldridge J, Blair S, et al. Enteral tube feeding for individuals with cystic fibrosis: Cystic fibrosis foundation evidence-informed guidelines. *J Cyst Fibros.* 2016;15:724-735.
8. Mandal A, Kabra SK, Lodha R. Cystic Fibrosis in India: Past Present and Future. *J Pulm Med Respir Res.* 2015;1:002.
9. Sharma GD. Cystic Fibrosis Treatment and Management. Updated Feb, 2018. Available on [medscape.com](https://www.medscape.com).
10. Hoiby N. Recent advances in the treatment of *Pseudomonas aeruginosa* infections in cystic fibrosis. *BMC Med.*2011;9:32.
11. Ehsan Z, Clancy JP. Management of *Pseudomonas aeruginosa* infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. *Future Microbiol.*2015;10:1901-1902.
12. William S, Ashworth, McAlweenie A, Poole S, Hodson M, Westaby D. Percutaneous endoscopic gastrostomy feeding in patients with cystic fibrosis. *Gut.*1999;44:87-90.
13. Cystic Fibrosis Foundation. FDA Approves New CFTR Modulator Treatment for Cystic Fibrosis. Available on <https://www.cff.org/News/News-Archive/2018/FDA-Approves-New-CFTR-Modulator-Treatment-for-Cystic-Fibrosis/>. Accessed on 1st June 2018.